Skip to main content
Not Found
Digital Seminar

Psychedelics in Therapy: New Ways to Catalyze Healing


Speaker:
Michael Mithoefer, MD
Duration:
1 Hour 56 Minutes
Language:
Presented in EN, subtitles in EN and FR, handouts in EN and FR
Format:
Audio and Video
Copyright:
Jan 12, 2021
Product Code:
NOS096105
Media Type:
Digital Seminar

Choose a price item
Choose additional price

Description

As psychiatry struggles to develop new, more effective treatments, clinical trials combining psychotherapy and the drug MDMA, also known as Ecstasy, are producing stunning results. New research suggests that incorporating psychedelics like MDMA and psilocybin into talk therapy can dramatically boost outcomes with an array of issues, including PTSD, anxiety, depression, relationship blocks, even drug addiction. If ongoing trials continue with favorable results, FDA approval for certified therapists to use MDMA- and psilocybin-assisted therapy in their practices could be on the horizon. Guided in this recording by the psychiatrist at the helm of the MDMA-assisted psychotherapy trials, you’ll explore:  

  • The rationale for using drugs like MDMA, psilocybin and other psychedelics as catalysts for psychotherapy 
  • The MDMA-assisted psychotherapy process, illustrated with video clips 
  • How these inner-directed approaches to therapy respect and support clients’ innate healing intelligence 
  • New opportunities for psychotherapists to receive training in this approach 

Credit


Canada Credit - *

NOTE: Tuition includes one free CE Certificate (participant will be able to print the certificate of completion after passing the online post-test (80% passing score) and completing the evaluation). Instructional methods will include PowerPoint, didactic lecture, and others.

Continuing Education Information:  Listed below are the continuing education credit(s) currently available for this non-interactive self-study package. Program content is reviewed periodically per accrediting board rules for currency and appropriateness for credit. Credit approvals are subject to change. Please note, your licensing board dictates whether self-study is an acceptable form of continuing education, as well as which credit types are acceptable for continuing education hours. Please refer to your licensing board's rules and regulations. If your profession is not listed, please contact your licensing board to determine your continuing education requirements and check for reciprocal approval. 
For other credit inquiries not specified below, please contact info@pesi.com or 800-844-8260 before purchase.

Materials that are included in this course may include interventions and modalities that are beyond the authorized practice of your profession.  As a licensed professional, you are responsible for reviewing the scope of practice, including activities that are defined in law as beyond the boundaries of practice in accordance with and in compliance with your profession's standards.  

For Planning Committee disclosures, please see the statement above.  For speaker disclosures, please see the faculty biography.

 


Canada Credit - ---

Earn up to 2.0 CE hours. Please see below, for more details, as credit amounts vary by jurisdiction and profession. 


Canada Credit - Canadian Counsellors and Psychotherapists

PESI, Inc. is approved by the Canadian Counselling and Psychotherapy Association to offer continuing education for counsellors and psychotherapists. PESI, Inc. maintains responsibility for the program. This self-study activity is approved for 2.0 credit hours.


Canada Credit - Canadian Psychologists

PESI, Inc. is approved by the Canadian Psychological Association to offer continuing education for psychologists. PESI, Inc. maintains responsibility for the program. This program is approved for 2.0 self-study continuing education hours. Full credit statement at: www.pesi.com/cpa-statement


Canada Credit - Other Professions

This self-study activity qualifies for 2.0 continuing education clock hours as required by many national and local licensing boards and professional organizations. Save your activity advertisement and certificate of completion, and contact your own board or organization for specific requirements.



Handouts

Speaker

Michael Mithoefer, MD's Profile

Michael Mithoefer, MD Related seminars and products


Michael Mithoefer, MD, is clinical assistant professor of psychiatry at the Medical University of South Carolina. In 2009, he completed & published the first FDA approved clinical trial of MDMA assisted psychotherapy for treatment-resistant PTSD, followed by completion of a Phase II trial. He is overseeing a multisite Phase III study of MDMA-assisted psychotherapy in 13 sites around the US (including the Trauma Research Foundation), and another MDMA-assisted psychotherapy multisite study in Europe and Israel.

 

Speaker Disclosures:
Financial: Dr. Michael Mithoefer has employment relationships with Columbia University, Bassett Healthcare Network, University of South Carolina, Lykos Therapeutics and has ownership interest in Awakn Life Sciences. He is a sub-investigator and therapist at Zen Therapeutics and a consultant with MAPS. Dr. Mithoefer receives a speaking honorarium and recording royalties from PESI, Inc.
Non-financial: Dr. Michael Mithoefer is a fellow of the American Psychiatric Association.


Additional Info

Program Information

Access for Self-Study (Non-Interactive)

Access never expires for this product.


Questions?

Visit our FAQ page at https://www.pesicanada.com/faq or contact us at https://www.pesicanada.com/contact-us


Objectives

  1. Evaluate the results of clinical trials of MDMA-assisted psychotherapy for PTSD and their treatment implications. 
  2. Determine the clinical uses of MDMA-assisted psychotherapy in the treatment of trauma. 
  3. Appraise the role therapists play in the sessions while the client is under the effects of these drugs, and how to facilitate the talk-therapy sessions that precede and follow it to improve client outcomes. 
  4. Assess the risks and limitations of MDMA and psilocybin-assisted psychotherapy. 

Outline

  • History of MDMA and Psilocybin 
  • Physiological effects and side effects, risk/benefit profile 
  • Design of past and ongoing non-profit-sponsored clinical trials of MDMA-assisted psychotherapy 
  • Results of Six Completed MDMA Phase 2 Clinical trials 
  • Design of ongoing Phase 3 Trials of MDMA-assisted psychotherapy 
  • Overview of psilocybin clinical trials 
  • Status of FDA drug development – MDMA and Psilocybin, including Breakthrough Therapy Designation 
  • The manualized therapeutic method used in clinical trials of MDMA-assisted psychotherapy 
    • Essential elements of “inner directed” approach 
    • Illustrated with quotes and videos 
    • Challenges that may arise 
  • Therapist training program for MDMA-assisted psychotherapy 

Target Audience

  • Counselors
  • Social Workers
  • Psychologists
  • Psychotherapists
  • Therapists
  • Marriage & Family Therapists
  • Addiction Counselors
  • Case Managers
  • Physicians
  • Nurses
  • Other Mental Health Professionals

Reviews

5
4
3
2
1

Overall:      4.7

Total Reviews: 318

Satisfaction Guarantee
Your satisfaction is our goal and our guarantee. Concerns should be addressed to info@pesicanada.com.

Please wait ...

Back to Top